ERCC6L2 disease (ED) is an inherited bone marrow failure (BMF) syndrome that progresses with high penetrance to an erythroid, TP53-mutated myeloid malignancy. This study of 29 ED patients with longitudinal sampling demonstrates that ED is characterized by early, intense, and recurrent selection for TP53-mutant hematopoietic clones. The pattern of somatic evolution observed in ED implicates sustained p53-pathway attenuation as the dominant driver of progression from marrow failure to leukemia.
The investigators integrated whole-genome sequencing (WGS) and single-cell RNA sequencing across longitudinally collected samples from 29 individuals with genetically defined ERCC6L2 disease. The study design allowed mapping of clonal composition over time and across disease stages. Summary-level genomic data, including variant calls, allele frequencies, and inferred clonal composition, are provided in the manuscript and supplementary files. Individual-level sequence data are restricted under participant consent and EU General Data Protection Regulation (GDPR).
To contextualize the somatic evolution in ED, the authors compared ED findings to those in Shwachman-Diamond syndrome (SDS), another inherited marrow failure disorder with a propensity for TP53 mutations. This comparison highlighted disease-specific differences in the tempo and extent of TP53-mutant clone emergence and expansion.
ED patients showed a higher frequency of TP53 mutations than observed in SDS, with many patients harboring multiple independent TP53 mutations. The cohort demonstrated steeper age-related expansion of TP53-mutant clones in ED compared with SDS. Notably, all ED patients without detectable TP53 mutations were children in this cohort, indicating that TP53-mutant clones accumulate with age in ED and are detectable prior to overt malignancy.
The study identified a stage-dependent change in the spectrum of TP53 variants. During the bone marrow failure phase, missense TP53 mutations predominated. In contrast, patients with overt malignancy more often carried non-missense TP53 alterations, consistent with selection for biallelic TP53 inactivation as disease progressed. Multiple TP53 mutations were frequently present before malignant transformation, and the overall burden of multiple TP53 variants in ED exceeded that reported for sporadic TP53-mutated myeloid neoplasia.
Beyond TP53, the somatic driver gene landscape in ED was unexpectedly narrow. PPM1D was identified as the only recurrent non-TP53 driver across the cohort. No other recurrent driver genes comparable to TP53 or PPM1D were observed in these patients, underscoring the dominant role of p53-pathway attenuation in ED clonal selection.
Although ERCC6L2 encodes a protein implicated in DNA repair, the mutational patterns in ED did not reveal a distinct ED-specific mutational signature. Instead, the mutational spectra reflected age-associated processes. The absence of a unique DNA-repair–related signature suggests that disease progression is driven primarily by selection on the p53 pathway rather than by a distinctive mutagenic process tied to ERCC6L2 dysfunction.
Malignant progression in ED was accompanied by acquisition of complex karyotypes and recurrent chromosomal losses, notably involving chromosomes 5, 7, and the short arm of chromosome 12 (12p). These cytogenetic alterations were enriched in erythroid progenitors, supporting an erythroid-predominant trajectory of clonal expansion. The authors also observed localized hypermutation (kataegis) in progressing clones. The combined genomic and single-cell RNA data support a model of branched clonal evolution with erythroid-biased expansion of TP53-mutant and cytogenetically abnormal subclones.
Collectively, these results establish ED as a paradigm of preleukemic dependency on attenuation of the p53 pathway. Because TP53-driven clones appear early and expand longitudinally in ED, the disease offers a natural model for mapping the stepwise events leading to TP53-mutated leukemia. The dominance of TP53 and the scarcity of other recurrent drivers suggest that therapeutic or surveillance strategies focused on early detection of TP53-mutant clones and their erythroid expansion may be particularly relevant in ED and may inform understanding of TP53-mutated leukemias more broadly.
The study received institutional ethics approvals and all samples from living individuals were obtained after written informed consent. Detailed IRB approvals are described in the manuscript. Because the dataset derives from patients with a rare disease, individual-level genomic data cannot be deposited in a public repository under the participants' consent and GDPR constraints; however, summary-level variant information and clonal composition supporting the study conclusions are provided in the manuscript and supplementary material. The report is a preprint; peer review and additional validation may alter interpretations or extend findings.